BCG Treatment for Bladder Cancer: Schedule, Side Effects and Options
BCG Treatment in Brief
What it is: BCG (Bacillus Calmette-Guérin) is a weakened, live bacterium, related to the tuberculosis vaccine, that is put directly into the bladder through a catheter. It triggers an immune reaction in the bladder lining that destroys remaining cancer cells and lowers the chance of the cancer coming back or becoming invasive. It is a standard treatment after tumour removal (TURBT) for high-risk and some intermediate-risk non-muscle-invasive bladder cancer (high-grade Ta, T1 and carcinoma in situ). It is not used for cancer that has grown into the bladder muscle.
The usual schedule:
- Induction: one treatment a week for 6 weeks, usually starting 2 to 4 weeks after TURBT once the bladder has healed.
- Maintenance (SWOG schedule): 3 weekly treatments at 3 and 6 months, then every 6 months, for 1 year (intermediate risk) or up to 3 years (high risk) if tolerated.
- Each treatment: a catheter is passed, the BCG is run in, the catheter is removed and you hold the liquid in for up to 2 hours before passing urine.
Side effects after BCG: most people have burning when passing urine, frequency and urgency, and sometimes blood in the urine or a mild flu-like feeling for 1 to 2 days after each treatment. A fever above 38.5°C (101.3°F), shivering, or symptoms lasting more than 48 hours need a call to your urology team the same day, because BCG infection, although rare, needs treatment.
If supply is short or BCG stops working: because of ongoing BCG shortages, some centres reserve full-dose BCG for the highest-risk patients and use reduced doses or intravesical chemotherapy for others (see below). If cancer persists or returns despite adequate BCG, options include bladder removal (cystectomy), pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept (N-803) with BCG, an intravesical gemcitabine-releasing system, intravesical chemotherapy and clinical trials (see options).
Quick Facts About BCG Therapy
- Gold standard treatment for high-risk non-muscle-invasive bladder cancer
- Uses weakened tuberculosis bacteria as immunotherapy
- Instilled directly into bladder through catheter (intravesical)
- Reduces cancer recurrence by 40% and progression by 25-30%
- Treatment involves induction (6 weekly treatments) plus maintenance (1 to 3 years)
- Very common urinary side effects but rarely serious complications
What is BCG Therapy?
BCG (Bacillus Calmette-Guérin) therapy is a form of immunotherapy that uses a weakened (attenuated) strain of Mycobacterium bovis, the bacteria that causes tuberculosis in cattle. Originally developed as a tuberculosis vaccine in 1921, BCG was discovered to have powerful anti-cancer properties and has been used to treat bladder cancer since the 1970s.
Unlike traditional chemotherapy that directly kills cancer cells, BCG works by stimulating your own immune system to attack cancer cells in the bladder lining. It is administered as intravesical therapy, meaning the BCG solution is placed directly into the bladder through a catheter, where it stays for about two hours before being urinated out.
Key Points
- BCG is the most effective treatment for preventing recurrence and progression of high-risk non-muscle-invasive bladder cancer
- It has been the gold standard therapy for over 40 years with extensive research supporting its use
- Treatment is local (confined to the bladder), minimizing systemic side effects
- Success depends on completing both induction and maintenance therapy
- Periodic supply shortages have led to research into alternative treatments
How BCG Therapy Works
BCG therapy works through a complex immune response that is still not completely understood. Here's what we know:
Mechanism of Action
- Local Immune Activation: When BCG is instilled into the bladder, it attaches to the bladder wall and is taken up by immune cells in the bladder lining (urothelium).
- Inflammatory Response: The presence of BCG bacteria triggers a strong local inflammatory response. Your immune system recognizes BCG as foreign and mounts an aggressive defense.
- Immune Cell Recruitment: Multiple types of immune cells are recruited to the bladder, including:
- T lymphocytes (CD4+ and CD8+ cells)
- Natural killer (NK) cells
- Macrophages
- Dendritic cells
- Cytokine Release: Activated immune cells release powerful signaling molecules (cytokines) like interferon-gamma, interleukins, and tumor necrosis factor that help coordinate the anti-cancer response.
- Cancer Cell Destruction: The activated immune system doesn't just attack BCG - it also recognizes and destroys cancer cells in the bladder lining. This creates a "bystander effect" where the immune response against BCG extends to bladder cancer cells.
- Immune Memory: With repeated BCG treatments, the immune system develops memory, maintaining long-term surveillance against cancer cell recurrence.
Why Weakened TB Bacteria?
The BCG strain used for bladder cancer treatment is the same live but weakened bacteria used as a TB vaccine worldwide. Because it's alive but attenuated, it can replicate slightly in the bladder, creating a sustained immune response, but it cannot cause actual tuberculosis disease in healthy individuals. This unique property makes it an ideal immunotherapy agent.
When BCG Therapy is Used
BCG is primarily used for non-muscle-invasive bladder cancer (NMIBC), particularly in high-risk situations. It is not used for muscle-invasive disease, which requires more aggressive treatment like surgery or chemotherapy.
Primary Indications
- Carcinoma in situ (CIS): Flat, high-grade cancer confined to the bladder lining - BCG is the treatment of choice
- High-grade Ta tumors: Superficial but aggressive cancers with high recurrence risk
- T1 tumors: Cancer invading the connective tissue beneath the bladder lining but not the muscle
- Recurrent Ta/T1 tumors: Even if low-grade, multiple recurrences increase the indication for BCG
- High-risk features: Multiple tumors, large tumors (>3cm), or tumors with lymphovascular invasion
Risk Stratification
High-Risk NMIBC
BCG Recommended
- Any CIS
- High-grade T1
- High-grade Ta with high-risk features
- BCG significantly improves outcomes
Intermediate-Risk NMIBC
BCG May Be Used
- Low-grade recurrent Ta
- Multiple low-grade tumors
- Decision based on individual factors
- Alternative: intravesical chemotherapy
Low-Risk NMIBC
BCG Not Recommended
- Single, small, low-grade Ta tumor
- Low recurrence risk
- Single chemotherapy instillation may suffice
- BCG risks outweigh benefits
Gold Standard Status
For high-grade Ta, T1, and CIS bladder cancer, BCG therapy with maintenance is considered the gold standard treatment worldwide. Multiple randomized controlled trials and decades of clinical experience have established it as the most effective therapy for preventing recurrence and progression to muscle-invasive disease.
BCG Treatment Schedule
BCG therapy consists of two phases: induction and maintenance. Completing both phases is critical for optimal outcomes.
Induction Phase
Week 1: First Treatment
Initial BCG instillation, typically 3-4 weeks after tumor resection to allow healing
Weeks 2-6: Weekly Treatments
One BCG instillation per week for a total of 6 consecutive weeks
Week 12: First Evaluation
Cystoscopy, urine cytology, and sometimes bladder biopsy to assess response
Induction Success Rates
After the 6-week induction course, approximately 60-70% of patients with CIS will achieve a complete response. However, without maintenance therapy, many will experience recurrence within 1-2 years. This is why maintenance is essential.
Maintenance Phase
Multiple maintenance schedules exist, but the most studied is the Southwest Oncology Group (SWOG) protocol:
SWOG Maintenance Protocol
- 3 months after induction: 3 weekly instillations
- 6 months after induction: 3 weekly instillations
- Every 6 months thereafter: 3 weekly instillations
- Total duration: Up to 3 years (maximum benefit)
- Minimum duration: At least 1 year for high-risk disease
Note: Some protocols use modified schedules with less frequent maintenance, but the SWOG protocol has the strongest evidence for preventing recurrence and progression.
Alternative Maintenance Schedules
| Protocol | Schedule | Duration | Notes |
|---|---|---|---|
| SWOG | 3 weeks at 3, 6, 12, 18, 24, 30, 36 months | 3 years | Most evidence-based, gold standard |
| Modified SWOG | 3 weeks at 3, 6, 12, 18, 24 months | 2 years | Reduced burden, still effective |
| EORTC | 3 weeks at 3, 6, 12, 18, 24, 30, 36 months | 3 years | European standard, similar to SWOG |
| Reduced Schedule | Monthly or every 3 months | 1-2 years | Used during BCG shortages |
One Year or Three Years of BCG?
This is the question patients ask most often once induction is behind them, and the answer depends on risk group rather than preference.
- Intermediate-risk disease: One year of maintenance is generally sufficient. The large EORTC 30962 trial found no significant advantage for three years over one year in this group, so the extra two years of instillations, cystoscopies and side effects buy little.
- High-risk disease (high-grade T1, CIS, multifocal high-grade Ta): Three years is the standard. In the same trial, high-risk patients on three years of maintenance had significantly fewer recurrences than those stopping at one year, although neither duration changed progression to muscle-invasive disease or overall survival.
Two practical caveats. First, dose reduction is not a shortcut — reduced-dose BCG for three years did not match full-dose three-year therapy in high-risk patients. Second, completing the course matters more than the nominal duration: a patient who tolerates one full year is better served than one who abandons a three-year plan after four months. If side effects are making instillations intolerable, raise it early, because dose reduction or a short delay is usually preferable to stopping altogether.
Importance of Maintenance Therapy
Studies consistently show that induction alone is not enough. Maintenance BCG therapy:
- Reduces recurrence rates by an additional 30-40% compared to induction alone
- Decreases progression to muscle-invasive disease by 25-30%
- May reduce bladder cancer mortality
- Benefits increase with longer duration (3 years superior to 1 year)
Bottom line: Don't skip maintenance therapy unless there are medical contraindications or intolerable side effects.
The BCG Procedure: What to Expect
Understanding what happens during a BCG treatment can help reduce anxiety and ensure you're properly prepared.
Before Your Treatment
Pre-Treatment Checklist
Step-by-Step Procedure
-
Positioning
You'll lie on an exam table, similar to positioning for cystoscopy. The genital area is cleaned with antiseptic solution.
-
Catheter Insertion
A small, soft catheter (thin tube) is gently inserted through the urethra into the bladder. Local anesthetic gel is typically used to minimize discomfort. The bladder is drained of any remaining urine.
-
BCG Instillation
The BCG solution (usually 50ml) is slowly instilled into the bladder through the catheter. You may feel a sensation of bladder fullness.
-
Catheter Removal
Once the full dose is instilled, the catheter is removed. The entire instillation process takes just a few minutes.
-
Retention Period (2 Hours)
You must retain the BCG in your bladder for approximately 2 hours. During this time:
- Change position every 15-30 minutes (lie on back, each side, stomach) to ensure BCG contacts all bladder surfaces
- Avoid drinking fluids during the 2-hour period
- You may read, watch videos, or rest
- Some clinics allow you to go home, others require you to stay
-
Voiding
After 2 hours, you urinate to empty the BCG from your bladder. Special toilet precautions are required (see below).
Catheter Discomfort
Most patients describe catheter insertion as briefly uncomfortable but not painful when anesthetic gel is used. If you've had previous catheterizations, BCG catheter insertion is typically easier and quicker than cystoscopy catheters. Relaxation and slow, deep breathing can help reduce discomfort.
After Voiding: Toilet Hygiene
Important Safety Precautions
BCG bacteria remain viable in your urine for up to 6 hours after treatment. Follow these precautions to protect household members:
- Sit to urinate (men included) to prevent splashing
- After urinating: Add 2 cups (500ml) of undiluted bleach to the toilet
- Wait 15 minutes before flushing to allow bleach to kill BCG bacteria
- Wash hands thoroughly with soap and water
- Clean any spills immediately with bleach solution
- For 6 hours after each treatment: Repeat the bleach process with each urination
- Wash genitals carefully after treatment and before sexual activity
Post-Treatment Care First 24-48 Hours
- Hydration: Drink plenty of fluids after the 2-hour retention period to help flush the bladder
- Activity: Resume normal activities, but avoid strenuous exercise for 24 hours
- Sexual activity: Avoid for 48 hours after treatment (BCG can be transmitted)
- Monitoring: Watch for concerning symptoms (see side effects section)
- Medications: Take prescribed medications as directed (e.g., pain relievers, antispasmodics)
Side Effects of BCG Therapy
BCG causes side effects in the majority of patients because it deliberately triggers an immune response. Most side effects are local (bladder-related), mild to moderate, and temporary. However, it's important to recognize potentially serious complications.
Common Side Effects (Affect 80-90% of Patients)
Urinary Frequency
Very CommonNeeding to urinate more often than usual, sometimes every 30-60 minutes. Usually peaks 2-4 hours after treatment and improves within 1-2 days.
Management: Stay near a bathroom, avoid bladder irritants (caffeine, alcohol, spicy foods)
Urinary Urgency
Very CommonSudden, strong need to urinate immediately. Can be challenging to control.
Management: Antispasmodic medications (oxybutynin, tolterodine), bladder training exercises
Dysuria (Painful Urination)
Very CommonBurning or stinging sensation during urination. Can range from mild to severe.
Management: Phenazopyridine (Pyridium), increased fluid intake, warm sitz baths
Hematuria (Blood in Urine)
Very CommonPink, red, or cola-colored urine from bladder inflammation. Usually microscopic but can be visible.
Management: Increase fluids, rest. Contact doctor if heavy bleeding or clots occur
Flu-like Symptoms
Very CommonMalaise, fatigue, body aches, mild fever (<100.4°F), chills. Usually starts 4-6 hours after treatment and lasts 24-48 hours.
Management: Acetaminophen (Tylenol), rest, fluids. Avoid NSAIDs (may interfere with BCG response)
Nausea
CommonMild to moderate nausea, rarely with vomiting. Part of systemic immune response.
Management: Small, frequent meals; ginger; anti-nausea medications if needed
Side Effects Often Worsen With Repeated Treatments
It's normal for bladder symptoms to become more pronounced with each successive BCG treatment during the induction phase. This is actually a sign that your immune system is responding. Symptoms typically peak during weeks 4-6 of induction, then improve during maintenance. If symptoms become intolerable, discuss dose reduction or treatment delays with your urologist.
When to Contact Your Doctor
Call Your Doctor Immediately If You Experience:
- High fever: Temperature above 103°F (39.4°C) or fever lasting more than 48 hours
- Fever above 101°F (38.3°C) for more than 2 days
- Severe bladder pain or spasms not relieved by medication
- Complete inability to urinate (urinary retention)
- Heavy bleeding with clots or blood that doesn't clear with increased fluids
- Skin rash especially with fever
- Joint pain and swelling (arthritis)
- Difficulty breathing, persistent cough
- Severe fatigue or confusion
- Eye redness or vision changes
These could indicate BCG infection (BCGosis) or BCG sepsis - rare but serious complications requiring immediate treatment.
Serious but Rare Complications (<5% of Patients)
- BCGosis: Systemic BCG infection outside the bladder (lungs, liver, joints). Requires anti-tuberculosis antibiotics for 3-6 months.
- BCG sepsis: Life-threatening bloodstream infection with BCG. Extremely rare (<1%) but requires hospitalization, IV antibiotics, and possibly ICU care.
- Granulomatous prostatitis (men): BCG infection of the prostate, causing pain, urinary symptoms, and elevated PSA.
- Contracted bladder: Chronic inflammation leading to reduced bladder capacity (very rare with modern protocols).
- Reiter's syndrome: Reactive arthritis affecting joints, eyes, and urethra.
Managing Side Effects: Medications
| Symptom | Medication Options | Notes |
|---|---|---|
| Painful urination | Phenazopyridine (Pyridium, Azo) | Turns urine orange; relieves burning |
| Urgency/frequency | Oxybutynin, Tolterodine, Solifenacin | Antispasmodics; reduce bladder spasms |
| Flu symptoms, mild fever | Acetaminophen (Tylenol) | Avoid NSAIDs - may reduce BCG effectiveness |
| Nausea | Ondansetron, Metoclopramide | Usually not needed; try ginger first |
| Bladder pain | Acetaminophen, warm sitz baths | Severe pain may require treatment delay |
How Effective is BCG Therapy?
BCG is the most effective intravesical therapy for high-risk non-muscle-invasive bladder cancer, with decades of clinical evidence supporting its use.
BCG vs. Other Treatments
| Treatment | Recurrence Prevention | Progression Prevention | Best For |
|---|---|---|---|
| BCG + Maintenance | Excellent (40% reduction) | Very Good (27% reduction) | High-risk NMIBC, CIS |
| BCG Alone (no maintenance) | Good (25% reduction) | Moderate (10-15% reduction) | Not recommended - use maintenance |
| Mitomycin C | Moderate (15-20% reduction) | Minimal | Intermediate-risk, BCG-intolerant |
| Gemcitabine | Fair to Moderate | Unknown (limited data) | BCG-unresponsive, alternative therapy |
| TURBT Alone | Poor (baseline) | Poor (baseline) | Low-risk only |
Factors Affecting BCG Success
- Complete TURBT: Complete tumor resection before BCG is critical
- Timing: Starting BCG 3-4 weeks after TURBT (not too early/late)
- Maintenance therapy: Completing full maintenance dramatically improves outcomes
- BCG strain and dose: Full dose is more effective than reduced dose
- Patient factors: Immunocompetent patients respond better
- Tumor characteristics: Smaller, fewer tumors have better outcomes
- BCG naïve: First-time BCG users respond better than those who've had BCG before
Long-term Outcomes with BCG
Long-term studies show that BCG with 3-year maintenance provides durable benefit:
- 5-year recurrence-free survival: 35-45%
- 10-year recurrence-free survival: 25-30%
- Bladder preservation rate: 70-80% avoid cystectomy
- Disease-specific survival: 85-90% at 10 years for high-risk NMIBC
These outcomes are significantly better than any other bladder-preserving treatment option for high-risk disease.
Contraindications: When BCG Should Not Be Used
BCG is a live bacterial vaccine and can cause serious infections in certain situations. Understanding contraindications is essential for safety.
Absolute Contraindications (BCG Must Not Be Given)
- Active urinary tract infection (UTI): Treat infection first, wait until urine culture is negative
- Gross hematuria (visible blood in urine): Indicates bladder trauma or inflammation; BCG could enter bloodstream
- Recent traumatic catheterization: Wait 1-2 weeks for urethra/bladder to heal
- Immunosuppression:
- HIV/AIDS with low CD4 count
- Active immunosuppressive therapy (chemotherapy, high-dose steroids, biologic immunosuppressants)
- Organ transplant recipients on anti-rejection drugs
- Active tuberculosis: BCG could worsen infection or interfere with TB treatment
- Pregnancy: BCG can harm the fetus; effective contraception required during treatment
- Active BCG infection (BCGosis): Cannot give more BCG while treating systemic BCG infection
Relative Contraindications (Use With Caution or Avoid)
- Fever: Delay treatment until afebrile for 24 hours
- Recent TURBT (within 2 weeks): Allow adequate healing time
- Bladder perforation during TURBT: Delay BCG for 4-6 weeks minimum
- Small bladder capacity (<150ml): May not tolerate treatment
- Urinary incontinence: Cannot retain BCG for 2 hours
- History of TB exposure: Discuss with infectious disease specialist
- Severe systemic illness: May not tolerate immune response
- Age considerations: Very elderly or frail patients may have higher risk
Before Each BCG Treatment - Screening Checklist
Your Doctor Will Check:
Important: Don't Delay Unnecessarily, But Don't Rush
BCG must be given under safe conditions. If you have a contraindication:
- Address the issue (treat UTI, wait for healing, control fever)
- Resume BCG when safe - short delays (1-2 weeks) are acceptable
- Delays longer than 3 months may require restarting induction
- Discuss alternative treatments if BCG permanently contraindicated
Special Precautions During BCG Treatment
Infection Control at Home
- Toilet hygiene: Add bleach to toilet after each urination for 6 hours post-treatment
- Handwashing: Wash hands thoroughly after using bathroom
- Clean up spills: Use bleach solution for any urine spills
- Separate towels: Use your own towel; don't share with family members
- Laundry: Wash undergarments separately if soiled with urine on treatment day
Sexual Activity
Avoiding BCG Transmission to Partners
- Avoid sexual activity for 48 hours after each BCG treatment
- BCG can be transmitted through genital contact or body fluids
- Use condoms for at least 1 week after treatment for extra protection
- Partners can develop localized BCG infections (though rare)
- Women: BCG is contraindicated in pregnancy - use effective birth control
Activity and Exercise
- Day of treatment: Light activities only; avoid strenuous exercise
- Days after treatment: Resume normal activities as tolerated
- Hydration: Drink plenty of water (8-10 glasses daily) except during 2-hour retention
- Avoid bladder irritants: Limit caffeine, alcohol, spicy foods, artificial sweeteners
Monitoring and Follow-up
During Induction (Weeks 1-6)
- Weekly BCG treatments
- Report side effects to nurse or doctor
- Keep symptom diary
At 3 Months (12 Weeks)
- Cystoscopy and urine cytology
- Biopsy if suspicious areas seen
- Assess response to treatment
- Begin maintenance if responding
Every 3-6 Months During Maintenance
- Cystoscopy before each maintenance cycle
- Urine cytology
- Monitor for recurrence
After Completing BCG
- Cystoscopy every 3-6 months for 2 years
- Then every 6-12 months if no recurrence
- Lifelong surveillance needed
Travel and BCG Treatment
Planning Travel During BCG Therapy
- Weekly induction makes extended travel difficult (plan for 6 consecutive weeks)
- Maintenance cycles allow more flexibility (travel between 3-week cycles)
- Bring urologist's contact information when traveling
- International travel: Consider that BCG vaccine is not tuberculosis - carry documentation
- Avoid travel to areas with limited medical facilities during induction
Medication Interactions
- Avoid immunosuppressants: Steroids, biologics, chemotherapy can reduce BCG effectiveness
- Antibiotics: Some antibiotics (fluoroquinolones, rifampin) kill BCG - discuss with doctor
- NSAIDs (ibuprofen, aspirin): May reduce BCG immune response - use acetaminophen instead
- Anticholinergics for overactive bladder: Generally safe; often prescribed to manage BCG side effects
Full-Strength BCG, Reduced Doses and the BCG Shortage
BCG is a live bacterium that takes months to grow and is made by very few manufacturers. In the United States, the only BCG currently licensed for bladder cancer is the TICE strain, made by a single company, and supply has been limited since another manufacturer stopped producing its strain in 2019. Other countries use different strains (for example Tokyo-172, RIVM or Moreau) with their own supply problems.
What "full strength" means
A full-strength (full-dose) treatment is one standard vial of BCG mixed in saline and instilled into the bladder. A reduced dose is a fraction of a vial, usually one-half or one-third, which allows one vial to be shared between patients on the same day. Full-dose BCG is still the standard and is used in US hospitals and urology practices wherever supply allows; there is no list of "full-strength centres", and availability can change from month to month. If you want to know whether you will receive a full or reduced dose, ask your urologist directly.
How doctors ration BCG during shortages
American Urological Association (AUA) and related guidance during shortages suggests, in broad terms:
- Giving priority to induction for high-risk disease (high-grade T1 and CIS), the group that benefits most
- Using a reduced dose (one-half or one-third) when supply is tight, particularly for maintenance
- Shortening maintenance, for example to 1 year, or giving maintenance only to the highest-risk patients
- Using intravesical chemotherapy (such as gemcitabine, mitomycin, or sequential gemcitabine and docetaxel) instead of BCG for intermediate-risk disease, and sometimes for high-risk disease
- Offering early cystectomy to selected very-high-risk patients
Reduced-dose BCG appears reasonably effective for many people, but in the European trial comparing doses and durations, reduced-dose BCG did not fully match full-dose, 3-year treatment for high-risk disease. Trials are also testing other BCG strains and BCG alternatives; ask whether one is open near you.
If your BCG is delayed or reduced
- Ask whether your risk group means you should be prioritised for full-dose induction
- Ask whether intravesical chemotherapy would be an appropriate alternative while you wait
- Keep every surveillance cystoscopy appointment
- Ask about clinical trials of new intravesical treatments
- A short delay of a week or two in induction is not usually harmful, but do not let treatment drift without a plan
BCG-Unresponsive Disease
Unfortunately, not all patients respond to BCG therapy, and some who initially respond later experience recurrence. This is termed "BCG-unresponsive" or "BCG-refractory" disease.
Definitions
Doctors only call disease BCG-unresponsive after an adequate course of BCG: at least 5 of 6 induction doses plus at least 2 of 3 doses of maintenance, or at least 2 of 6 doses of a second induction course.
- BCG-unresponsive (the definition used by the FDA and AUA for drug approvals) means, after adequate BCG:
- carcinoma in situ (CIS) that persists or comes back within 12 months; or
- high-grade Ta or T1 cancer that comes back within 6 months; or
- high-grade T1 cancer at the first check after induction alone.
- BCG-relapsing: cancer that returns after a period free of disease, beyond those time limits. A further course of BCG may be an option.
- BCG-intolerant: unable to complete adequate treatment because of side effects.
Risk Factors for BCG Failure
- Carcinoma in situ (CIS) present at diagnosis
- T1 tumors (vs Ta)
- Multiple or large tumors
- Incomplete initial TURBT
- Early recurrence after TURBT (within 3 months)
- High-grade tumors
- Lymphovascular invasion
- Variant histology (micropapillary, plasmacytoid, etc.)
What Happens with BCG-Unresponsive Disease?
BCG-Unresponsive Disease is High-Risk
Patients with BCG-unresponsive NMIBC have:
- Higher progression risk: Up to 30-50% will progress to muscle-invasive disease
- Limited bladder-sparing options: Few effective alternatives to BCG
- Cystectomy often recommended: Bladder removal is most definitive treatment
- Need for close monitoring: Aggressive surveillance required if choosing bladder preservation
Standard of care: Radical cystectomy (bladder removal) is recommended for BCG-unresponsive disease in appropriate surgical candidates.
Alternative Treatments for BCG-Unresponsive Disease
For patients who cannot undergo cystectomy or wish to preserve their bladder, several alternative treatments are available, though none match BCG's long-term effectiveness.
FDA-Approved Options for BCG-Unresponsive Disease
Several bladder-sparing treatments have been approved since 2020, mostly on the basis of single-arm trials in people with BCG-unresponsive carcinoma in situ (with or without papillary tumours). Response rates below are from those trials, and responses do not last for everyone, so close cystoscopy follow-up continues.
1. Pembrolizumab (Keytruda)
- Type: PD-1 checkpoint inhibitor immunotherapy given into a vein every 3 or 6 weeks (not into the bladder)
- Approval: FDA 2020, for BCG-unresponsive high-risk NMIBC with CIS in people who cannot have, or choose not to have, cystectomy
- Results: about 4 in 10 had a complete response at 3 months in the KEYNOTE-057 trial; about half of those responses lasted a year or more
- Side effects: immune-related effects such as thyroid problems, colitis, hepatitis and pneumonitis. See our pembrolizumab page
2. Nadofaragene firadenovec (Adstiladrin)
- Type: gene therapy that delivers the interferon alfa-2b gene into bladder-lining cells; instilled into the bladder once every 3 months
- Approval: FDA December 2022, for BCG-unresponsive high-risk NMIBC with CIS
- Results: about half of patients with CIS had a complete response at 3 months in the pivotal trial
- Side effects: mainly bladder irritation, blood in the urine, tiredness and short-lived flu-like symptoms
3. Nogapendekin alfa inbakicept (Anktiva, also called N-803) with BCG
- Type: an IL-15 “superagonist” immune stimulant instilled into the bladder together with BCG
- Approval: FDA April 2024, for BCG-unresponsive NMIBC with CIS
- Results: roughly 7 in 10 patients with CIS had a complete response in the pivotal single-arm trial
- Note: because it is given with BCG, it depends on BCG being available
4. Gemcitabine intravesical system (TAR-200, Inlexzo)
- Type: a small flexible device placed in the bladder through a catheter that releases gemcitabine slowly over 3 weeks, then is removed and replaced
- Approval: FDA 2025, for BCG-unresponsive high-risk NMIBC with CIS
- Results: high complete response rates were reported in the single-arm SunRISe-1 trial; longer-term data are still maturing
5. Valrubicin (Valstar)
- Type: intravesical chemotherapy given weekly for 6 weeks
- Approval: FDA-approved for BCG-refractory CIS in people who cannot have immediate cystectomy
- Results: modest; complete responses in a minority of patients and often short-lived, so it is now used less often
Other agents, including the oncolytic virus cretostimogene grenadenorepvec and further checkpoint-inhibitor and antibody-drug conjugate approaches, are in late-stage trials or under regulatory review. Approval status changes quickly, so ask your urologist which options are available to you now.
Off-Label Alternatives (Not FDA-Approved for This Use)
3. Gemcitabine/Docetaxel Combination
- Type: Intravesical chemotherapy doublet
- Administration: Weekly for 6 weeks (induction), then monthly maintenance
- Response rate: 50-60% in clinical studies
- Advantage: Promising results, well-tolerated, readily available
- Disadvantage: Not FDA-approved (off-label use), long-term data limited
4. Mitomycin C
- Type: Intravesical chemotherapy
- Administration: Various schedules
- Response rate: 20-30% for BCG-unresponsive disease
- Advantage: Well-established, available, can be given with electromotive drug administration (EMDA) for improved absorption
- Disadvantage: Lower efficacy than BCG, skin reactions
5. Device-Assisted Therapies
- EMDA (Electromotive Drug Administration): Electric current enhances drug penetration into bladder wall
- Microwave hyperthermia + chemotherapy: Heat increases drug uptake
- Photodynamic therapy: Light-activated drugs destroy cancer cells
Clinical Trials
Clinical trials remain an important option for BCG-unresponsive disease and, during shortages, for people who cannot get BCG. Trials are testing new intravesical drugs and devices, gene and viral therapies, checkpoint inhibitors given with or instead of BCG, and alternative BCG strains. Our clinical trials guide explains how to search.
Radical Cystectomy: The Definitive Option
Despite advances in bladder-sparing therapies, radical cystectomy (surgical removal of the bladder) remains the guideline-recommended standard for BCG-unresponsive disease in people fit for surgery.
- Outcomes: long-term cancer control is high when cystectomy is done while the cancer is still confined to the bladder lining
- Timing matters: Earlier cystectomy has better outcomes than delayed
- Quality of life: Modern urinary diversion techniques (neobladder, continent diversion) offer good quality of life
- Who should consider: Younger, healthier patients with BCG-unresponsive disease, especially with high-risk features
- Who might avoid: Elderly, significant comorbidities, strong preference for bladder preservation
Decision-Making for BCG-Unresponsive Disease
This is a critical crossroad. Discuss thoroughly with your urologist:
- Risk of progression if trying bladder-sparing options
- Success rates of alternative treatments (generally lower than BCG)
- Your age, health status, and ability to undergo major surgery
- Quality of life considerations with and without bladder
- Surveillance burden and anxiety with bladder preservation
- Availability of clinical trials in your area
Frequently Asked Questions
What is BCG therapy for bladder cancer?
BCG therapy is a form of immunotherapy in which a weakened live bacterium (Bacillus Calmette-Guérin, related to the TB vaccine) is put into the bladder through a catheter. It provokes an immune reaction in the bladder lining that kills remaining cancer cells. It is used after tumour removal for high-risk and some intermediate-risk non-muscle-invasive bladder cancer, including carcinoma in situ.
What is the normal BCG schedule?
The standard course is induction with one instillation a week for 6 weeks, starting a few weeks after TURBT, followed by maintenance. The most widely used maintenance plan (the SWOG schedule) gives 3 weekly instillations at 3 and 6 months after starting, then every 6 months. Maintenance usually continues for 1 year in intermediate-risk disease and up to 3 years in high-risk disease, if tolerated and if supply allows.
Is one year or three years of BCG better?
For intermediate-risk disease, one year of maintenance appears to be enough. For high-risk disease, three years reduced recurrences compared with one year in the large EORTC trial, although it did not change progression or survival. Your urologist will weigh the benefit against side effects and BCG supply.
What side effects should I expect after BCG?
Most people have burning when passing urine, needing to go often or urgently, and sometimes blood in the urine or a mild flu-like feeling for 1 to 2 days after each treatment. Symptoms often build up during induction. Call your team the same day for a fever over 38.5°C (101.3°F), shivering, symptoms lasting more than 48 hours, joint pains, eye redness, a cough, or feeling generally unwell, because BCG can rarely spread beyond the bladder and needs treatment with anti-TB antibiotics.
How long do I hold BCG in my bladder?
Usually up to 2 hours. Your nurse may ask you to limit fluids for a few hours beforehand so your bladder does not fill too quickly. If you cannot hold it for the full time, tell your team; the treatment still works, and they may adjust things such as fluids or bladder-relaxing medicine for the next session.
Why do I need to be careful at home after BCG?
Because BCG is a live bacterium, small amounts pass out in your urine for several hours. Typical advice is to sit down to pass urine, add bleach to the toilet and leave it for about 15 minutes before flushing for the first 6 hours, wash your hands and genitals afterwards, and use condoms or avoid sex for the period your team advises (commonly at least 48 hours after each treatment, and some centres advise condoms throughout the course). This protects family members, especially anyone who is pregnant or has a weakened immune system.
What does full-strength BCG mean, and is it used in the US?
Full-strength BCG is one standard vial per treatment. During shortages some centres use one-half or one-third of a vial, mainly for maintenance or lower-risk patients. Full-dose BCG remains the standard of care in the US and is given wherever supply allows; availability varies between centres and over time, so ask your urologist which dose you will receive and why.
What if my BCG treatment is delayed or I miss a dose?
Short delays of a week or two, for example because of a urine infection or feeling unwell, are common and are not thought to reduce benefit much. Treatment is usually resumed where it left off. Longer gaps should be discussed with your urologist, who may repeat part of the course or check the bladder first.
What happens if BCG does not work?
If cancer persists or returns after an adequate course, it may be classed as BCG-unresponsive. Options then include bladder removal (radical cystectomy), which remains the standard for people fit for surgery, or bladder-sparing treatments such as pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept (N-803) with BCG, a gemcitabine-releasing bladder device, intravesical chemotherapy, or a clinical trial.
Is BCG the same as the tuberculosis vaccine?
It is the same type of bacterium, but used differently. For bladder cancer, a much larger amount of BCG is placed directly into the bladder rather than injected into the skin. It does not give you tuberculosis, although in rare cases the bacteria can cause an infection that needs antibiotics.
Can I test positive for TB after BCG treatment?
Possibly. BCG treatment can make a tuberculin skin test positive. If you need TB screening, tell the tester about your BCG treatment; an interferon-gamma blood test (IGRA) is less affected by BCG.
Is BCG used for muscle-invasive bladder cancer?
No. BCG only treats cancer confined to the bladder lining (Ta, T1 and carcinoma in situ). Cancer that has grown into the bladder muscle (T2 or higher) needs cystectomy, or chemotherapy and radiotherapy.
Can I get BCG if my immune system is weak?
Usually not. Significant immune suppression, for example from organ-transplant drugs, high-dose steroids or uncontrolled HIV, increases the risk of BCG spreading through the body, so other treatments are generally used. Discuss your situation with both your urologist and the doctor managing your immune condition.
Can BCG cure bladder cancer?
Many people treated with BCG remain free of recurrence for years, and BCG lowers the risk of the cancer becoming invasive. Bladder cancer can still return long after treatment, so regular cystoscopy continues even when BCG has worked.
Related Resources
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. BCG therapy decisions should be made in consultation with your urologic oncologist based on your specific cancer characteristics, health status, and individual circumstances. Always discuss risks, benefits, and alternatives with your healthcare team.
Last reviewed: October 2026. Guidelines and recommendations are based on current evidence and may change as new research emerges.